<DOC>
	<DOC>NCT00457015</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of DX-88 (ecallantide) versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.</brief_summary>
	<brief_title>Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)</brief_title>
	<detailed_description>This is a randomized placebo-controlled trial. The study is designed to assess the efficacy and safety of 30 mg subcutaneous ecallantide versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema. This study is conducted under Special Protocol Assessment with the FDA and is designed to provide pivotal efficacy data on ecallantide. These data are intended to support the marketing authorization of ecallantide in the treatment of acute attacks of hereditary angioedema. Efficacy and safety of ecallantide will be evaluated in this study.</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<criteria>10 years of age or older Executed informed consent Documented diagnosis of HAE (Type I or II) Presentation at the site within 8 hours of patient recognition of an moderate to severe HAE acute attack Receipt of an investigational drug or device, within 30 days prior to study treatment Receipt of noninvestigational C1INH within 7 days of treatment Receipt of DX88 (ecallantide) within 3 days prior to study treatment Diagnosis of acquired angioedema (AAE), estrogendependent angioedema or druginduced angioedema (including angiotensinconverting enzyme inhibitor induced angioedema) Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>